Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galactomannan is a polysaccharide composed of a mannose backbone with galactose side chains. In the supplied clinical-trial context, the exact asset appears to be enterally administered galactomannan used as a nutritional fiber intervention in critically ill patients, including explicit mention of \"beta-galactomannan\" tube feeding and related PHGG-enriched enteral formulas. Rather than acting through a discrete receptor pharmacology typical of drugs, galactomannan functions as a soluble, non-digestible carbohydrate that can modulate gastrointestinal tolerance, stool characteristics, and gut microbiota through prebiotic fermentation and downstream short-chain-fatty-acid generation. The evidence provided supports real-world clinical investigation as a nutritional or nutraceutical intervention in critical illness and post-gastrointestinal-surgery enteral nutrition, but not as a conventional pharmaceutical therapeutic with a single sponsor-developed molecular drug program.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galactomannan.